MGX Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -235.51% compared to Metagenomi Therapeutics, Inc.'s net margin of --. Metagenomi Therapeutics, Inc.'s return on equity of -41.18% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Metagenomi Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 543.68%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $52.58 which suggests that it could grow by 43.2%. Given that Metagenomi Therapeutics, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Metagenomi Therapeutics, Inc. is more attractive than Cogent Biosciences, Inc..

Metagenomi Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.

Metagenomi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metagenomi Therapeutics, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Metagenomi Therapeutics, Inc. quarterly revenues are $8.7M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Metagenomi Therapeutics, Inc.'s net income of -$20.4M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Metagenomi Therapeutics, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metagenomi Therapeutics, Inc. is 1.75x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -235.51% compared to Metagenomi Therapeutics, Inc.'s net margin of -82.06%. Metagenomi Therapeutics, Inc.'s return on equity of -41.18% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Metagenomi Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 543.68%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 11.43%. Given that Metagenomi Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Metagenomi Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Metagenomi Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Metagenomi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metagenomi Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Metagenomi Therapeutics, Inc. quarterly revenues are $8.7M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Metagenomi Therapeutics, Inc.'s net income of -$20.4M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Metagenomi Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metagenomi Therapeutics, Inc. is 1.75x versus 13.92x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -235.51% compared to Metagenomi Therapeutics, Inc.'s net margin of -1118.87%. Metagenomi Therapeutics, Inc.'s return on equity of -41.18% beat Nutriband, Inc.'s return on equity of -164.64%.

Metagenomi Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 543.68%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 269.46%. Given that Metagenomi Therapeutics, Inc. has higher upside potential than Nutriband, Inc., analysts believe Metagenomi Therapeutics, Inc. is more attractive than Nutriband, Inc..

Metagenomi Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.

Metagenomi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metagenomi Therapeutics, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Metagenomi Therapeutics, Inc. quarterly revenues are $8.7M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. Metagenomi Therapeutics, Inc.'s net income of -$20.4M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Metagenomi Therapeutics, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metagenomi Therapeutics, Inc. is 1.75x versus 20.26x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -235.51% compared to Metagenomi Therapeutics, Inc.'s net margin of -9210.61%. Metagenomi Therapeutics, Inc.'s return on equity of -41.18% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Metagenomi Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 543.68%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 169.93%. Given that Metagenomi Therapeutics, Inc. has higher upside potential than Ovid Therapeutics, Inc., analysts believe Metagenomi Therapeutics, Inc. is more attractive than Ovid Therapeutics, Inc..

Metagenomi Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.621%.

Metagenomi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metagenomi Therapeutics, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Metagenomi Therapeutics, Inc. quarterly revenues are $8.7M, which are larger than Ovid Therapeutics, Inc. quarterly revenues of $132K. Metagenomi Therapeutics, Inc.'s net income of -$20.4M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Metagenomi Therapeutics, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metagenomi Therapeutics, Inc. is 1.75x versus 16.13x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.